PRAX Stock Price, Praxis Precision Medicines Quote, Chart

Market Summary

USD51.02+2.18

Market Closed

4.46%

PRAX Stock Price

View Fullscreen

PRAX RSI Chart

PRAX Valuation

Market Cap

646.6M

Price/Earnings (Trailing)

-5.24

Price/Sales (Trailing)

264.23

EV/EBITDA

-3.75

Price/Free Cashflow

-5.82

PRAX Price/Sales (Trailing)

PRAX Profitability

EBT Margin

-6827.18%

Return on Equity

-176.95%

Return on Assets

-140.17%

Free Cashflow Yield

-17.2%

PRAX Fundamentals

PRAX Revenue

Revenue (TTM)

2.4M

Rev. Growth (Yr)

-10.72%

Rev. Growth (Qtr)

10.04%

PRAX Earnings

Earnings (TTM)

-123.3M

Earnings Growth (Yr)

34.72%

Earnings Growth (Qtr)

-9.12%

Breaking Down PRAX Revenue

Last 7 days

-6.8%

Last 30 days

-9.3%

Last 90 days

31.3%

Trailing 12 Months

4507.6%

How does PRAX drawdown profile look like?

PRAX Financial Health

Current Ratio

5.39

PRAX Investor Care

Buy Backs (1Y)

74.73%

Diluted EPS (TTM)

-18.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.3M	1.7M	2.1M	2.4M
2022	442.5K	614.0K	785.5K	957.0K
2021	205.5K	0	0	271.0K
2020	166.5K	0	0	140.0K
2019	0	0	0	193.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Praxis Precision Medicines Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 12, 2024	nemiroff alex	sold (taxes)	-2,277	44.65	-51.00	general counsel and secretary
Feb 12, 2024	mastrocola lauren	sold (taxes)	-2,143	44.65	-48.00	principal accounting officer
Feb 12, 2024	souza marcio	sold (taxes)	-12,100	44.65	-271	chief executive officer
Jan 07, 2024	kelly timothy edwin	sold (taxes)	-3,501	25.19	-139	chief financial officer
Jan 07, 2024	nemiroff alex	sold (taxes)	-2,241	25.19	-89.00	general counsel and secretary
Jan 07, 2024	mastrocola lauren	sold (taxes)	-881	25.19	-35.00	principal accounting officer
Jan 07, 2024	souza marcio	sold (taxes)	-10,529	25.19	-418	chief executive officer
Oct 05, 2023	desimone jill	bought	25,375	1.75	14,500	-
Jun 27, 2023	souza marcio	bought	10,587	1.0587	10,000	chief executive officer
May 12, 2023	nemiroff alex	acquired	10,330	0.884	11,686	general counsel and secretary

Which funds bought or sold PRAX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	Windmill Hill Asset Management Ltd	new	-	321,453	321,453	0.12%
Apr 19, 2024	PCG Wealth Advisors, LLC	new	-	788,196	788,196	0.38%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-39.00	-	-%
Mar 18, 2024	KINGDON CAPITAL MANAGEMENT, L.L.C.	sold off	-100	-8,892,000	-	-%
Mar 18, 2024	KINGDON CAPITAL MANAGEMENT, L.L.C.	new	-	15,447,400	15,447,400	0.97%
Mar 11, 2024	VANGUARD GROUP INC	new	-	8,264,500	8,264,500	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-9,514,640	-	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-158,368	-	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	sold off	-100	-57,000	-	-%
Feb 15, 2024	BARCLAYS PLC	new	-	206,000	206,000	-%

Are Funds Buying or Selling PRAX?

Are funds buying PRAX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PRAX

No. of Funds

Unveiling Praxis Precision Medicines Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	8.9%	823,626	SC 13G/A
Feb 14, 2024	tri locum partners lp	2.8%	248,761	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	7.9%	692,252	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	7.39%	633,345	SC 13G/A
Feb 14, 2024	verition fund management llc	8.0%	702,979	SC 13G
Feb 14, 2024	eventide asset management, llc	0.0%	0	SC 13G/A
Feb 14, 2024	pfm health sciences, lp	0.5%	6	SC 13G/A
Feb 13, 2024	avidity partners management lp	0%	0	SC 13G/A
Feb 13, 2024	huang james	0.0%	0	SC 13G/A
Feb 09, 2024	blackstone holdings i/ii gp l.l.c.	0.8%	70,273	SC 13G/A

Recent SEC filings of Praxis Precision Medicines Inc

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	424B5	Prospectus Filed
Mar 29, 2024	8-K	Current Report
Mar 27, 2024	424B5	Prospectus Filed
Mar 26, 2024	8-K	Current Report
Mar 12, 2024	EFFECT	EFFECT
Mar 08, 2024	CORRESP	CORRESP
Mar 08, 2024	UPLOAD	UPLOAD
Mar 05, 2024	10-K	Annual Report
Mar 05, 2024	8-K	Current Report
Mar 05, 2024	S-3	S-3

Peers (Alternatives to Praxis Precision Medicines Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-12.04%	-45.12%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Praxis Precision Medicines Inc News

Latest updates

Praxis Precision Medicines Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q1	2020Q4	2020Q1	2019Q4
Revenue	10.0%	515,000	468,000	781,000	683,000	576,833	470,667	364,500	258,333	152,167	46,000	87,000	128,000	-
Operating Expenses	9.0%	28,321,000	25,984,000	35,741,000	38,774,000	41,453,000	44,290,000	60,394,000	68,849,000	58,657,000	27,419,000	25,712,000	8,469,000	-
S&GA Expenses	13.9%	9,933,000	8,724,000	10,127,000	13,270,000	13,124,000	13,851,000	16,774,000	16,197,000	15,146,000	9,490,000	9,440,000	1,601,000	-
R&D Expenses	6.5%	18,388,000	17,260,000	25,614,000	25,504,000	28,329,000	30,439,000	43,620,000	52,652,000	43,511,000	17,929,000	16,272,000	6,868,000	-
EBITDA Margin	15.2%	-68.11	-80.33	-97.91	-125	-174	-212	-271	-376	-615	-467	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-5,000	-	-	-11,000	-
Earnings Before Taxes	-	-	-	-	-	-	-43,945,000	-	-	-58,587,000	-27,373,000	-25,706,000	-8,341,000	-
EBT Margin	15.2%	-68.27	-80.53	-98.16	-125	-174	-212	-272	-377	-616	-468	-	-	-
Net Income	-9.1%	-26,878,000	-24,632,000	-34,312,000	-37,455,000	-41,173,000	-43,945,000	-60,194,000	-68,717,000	-58,582,000	-27,373,000	-25,706,000	-8,330,000	-
Net Income Margin	24.0%	-50.38	-66.32	-92.18	-137	-223	-294	-378	-470	-616	-468	-	-	-
Free Cashflow	-3.0%	-23,911,000	-23,215,000	-31,214,000	-32,846,000	-28,806,000	-44,964,000	-57,319,000	-54,398,000	-45,388,000	-25,726,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-17.6%	88.00	107	133	98.00	115	137	180	240	293	324	354	279	303	120	48.00
Current Assets	-17.9%	85.00	103	130	94.00	111	132	176	234	287	319	348	279	302	116	45.00
Cash Equivalents	-19.6%	81.00	101	124	81.00	62.00	62.00	56.00	78.00	140	166	176	131	297	115	45.00
Net PPE	-16.0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-8.5%	18.00	20.00	28.00	34.00	39.00	32.00	42.00	48.00	42.00	28.00	20.00	14.00	16.00	11.00	8.00
Current Liabilities	-6.2%	16.00	17.00	24.00	30.00	34.00	29.00	39.00	45.00	38.00	25.00	16.00	14.00	16.00	10.00	7.00
Shareholder's Equity	-19.7%	70.00	87.00	106	64.00	76.00	105	139	191	251	296	334	266	287	-	-
Retained Earnings	-4.3%	-653	-627	-602	-568	-530	-489	-445	-385	-316	-258	-213	-176	-149	-123	-81.01
Additional Paid-In Capital	1.4%	724	714	708	633	607	595	585	577	568	554	547	443	437	-	-
Shares Outstanding	-93.2%	9.00	129	129	58.00	-	46.00	45.00	45.00	45.00	42.00	40.00	38.00	-	-	-
Float	-	-	-	147	-	-	-	104	-	-	-	761	-	-	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-2.8%	-23,861	-23,215	-31,214	-32,846	-28,806	-44,919	-57,209	-54,109	-44,857	-23,962	-30,013	-25,722	-20,228	-13,882	-9,944	-8,569	-	-
Share Based Compensation	-0.6%	5,726	5,763	5,775	7,593	6,366	6,730	7,611	7,886	6,106	6,521	5,400	4,666	3,826	953	285	147	-	-
Cashflow From Investing	-Infinity%	-50.00	-	5,000	34,000	22,594	47,955	34,890	-8,550	10,169	13,550	-24,229	-140,010	-	-	-	-	-	-
Cashflow From Financing	-	4,126	-	69,675	18,070	5,387	3,365	504	1,209	7,713	212	99,385	276	202,064	108,906	23,446	-30,000	-	-

PRAX Income Statement

2023-12-31

Consolidated Statements of Operations
$ in Thousands

12 Months Ended

Dec. 31, 2023

USD ($)

$ / shares

shares

Dec. 31, 2022

USD ($)

$ / shares

shares

Income Statement [Abstract]

Collaboration revenue

$ 2,447

$ 0

Operating expenses:

Research and development

86,766

155,040

General and administrative

42,054

59,946

Total operating expenses

128,820

214,986

Loss from operations

(126,373)

(214,986)

Other income:

Other income, net

3,096

957

Total other income

3,096

957

Net loss

$ (123,277)

$ (214,029)

Net loss per share attributable to common stockholders, basic (in usd per share) | $ / shares

^[1]

$ (18.69)

$ (69.65)

Net loss per share attributable to common stockholders, diluted (in usd per share) | $ / shares

^[1]

$ (18.69)

$ (69.65)

Weighted average common shares outstanding, basic (in shares) | shares

^[1]

6,594,316

3,073,100

Weighted average common shares outstanding, diluted (in shares) | shares

^[1]

6,594,316

3,073,100

[1]	Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details.

PRAX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)

Dec. 31, 2023

Dec. 31, 2022

Current assets:

Cash and cash equivalents

$ 81,300,000

$ 61,615,000

Marketable securities

0

38,874,000

Prepaid expenses and other current assets

3,580,000

10,351,000

Total current assets

84,880,000

110,840,000

Property and equipment, net

588,000

971,000

Operating lease right-of-use assets

2,064,000

2,901,000

Other non-current assets

416,000

Total assets

87,948,000

115,128,000

Current liabilities:

Accounts payable

5,815,000

14,672,000

Accrued expenses

7,416,000

15,850,000

Current operating lease liabilities

1,126,000

1,005,000

Current portion of deferred revenue

1,392,000

2,818,000

Total current liabilities

15,749,000

34,345,000

Long-term liabilities:

Non-current portion of operating lease liabilities

1,369,000

2,495,000

Non-current portion of deferred revenue

1,161,000

2,182,000

Total liabilities

18,279,000

39,022,000

Commitments and contingencies (Note 8)

Stockholders’ equity:

Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2023 and December 31, 2022

^[1]

0

Common stock, $0.0001 par value; 150,000,000 shares authorized; 8,791,877 shares issued and outstanding as of December 31, 2023, and 3,292,163 shares issued and outstanding as of December 31, 2022

^[1]

13,000

5,000

Additional paid-in capital

723,577,000

606,918,000

Accumulated other comprehensive loss

0

(173,000)

Accumulated deficit

(653,921,000)

(530,644,000)

Total stockholders’ equity

69,669,000

76,106,000

Total liabilities and stockholders’ equity

$ 87,948,000

$ 115,128,000

[1]	Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details.

About Praxis Precision Medicines Inc

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.

CEO	Mr. Marcio Souza M.B.A.
WEBSITE	https://praxismedicines.com
INDUSTRY	Biotechnology
EMPLOYEES	109

Praxis Precision Medicines Inc Frequently Asked Questions

What is the ticker symbol for Praxis Precision Medicines Inc? What does PRAX stand for in stocks?

PRAX is the stock ticker symbol of Praxis Precision Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Praxis Precision Medicines Inc (PRAX)?

As of Tue Apr 23 2024, market cap of Praxis Precision Medicines Inc is 646.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRAX stock?

You can check PRAX's fair value in chart for subscribers.

What is the fair value of PRAX stock?

You can check PRAX's fair value in chart for subscribers. The fair value of Praxis Precision Medicines Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Praxis Precision Medicines Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PRAX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Praxis Precision Medicines Inc a good stock to buy?

The fair value guage provides a quick view whether PRAX is over valued or under valued. Whether Praxis Precision Medicines Inc is cheap or expensive depends on the assumptions which impact Praxis Precision Medicines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRAX.

What is Praxis Precision Medicines Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, PRAX's PE ratio (Price to Earnings) is -5.24 and Price to Sales (PS) ratio is 264.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRAX PE ratio will change depending on the future growth rate expectations of investors.